Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to uncover why a deadly lung disease is often diagnosed too late

NCT ID NCT06998329

Knowledge-focused Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how long it takes for people in Brazil to get a correct diagnosis of pulmonary arterial hypertension (PAH), a rare and serious lung disease. Researchers will review medical records of about 139 adults diagnosed in the last five years to find out what causes delays. The goal is to help doctors diagnose PAH earlier, which could lead to better treatment and outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 139 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH), confirmed by right heart catheterization, who are followed at specialized pulmonary hypertension referral centers in Brazil. Eligible participants must have documented or estimated date of symptom onset and a recorded date of confirmed diagnosis. The study includes patients from diverse geographic regions and healthcare settings to reflect real-world diagnostic practices.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Availability of documented or estimated date of first symptom suggestive of PAH. * Availability of documented date of confirmed PAH diagnosis. Exclusion Criteria: * Patients with pulmonary hypertension not classified as Group 1 (e.g., due to left heart disease, chronic lung disease, or chronic thromboembolic disease). * Patients with insufficient data to determine either the date of symptom onset or the date of confirmed diagnosis. * Patients diagnosed only clinically or by echocardiography, without confirmation by right heart catheterization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension Pulmonary arterial hypertension (PAH) Pulmonary arterial hypertension (PAH) (who group 1 PH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • InCor - Universidade de São Paulo

    RECRUITING

    São Paulo, São Paulo, 05048000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.